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ABSTRACT
Background Amyotrophic lateral sclerosis (ALS) is a
progressive and usually fatal neurodegenerative disease.
Survival from diagnosis varies considerably. Several
prognostic factors are known, including site of onset
(bulbar or limb), age at symptom onset, delay from
onset to diagnosis and the use of riluzole and non-
invasive ventilation (NIV). Clinicians and patients would
beneﬁt from a practical way of using these factors to
provide an individualised prognosis.
Methods 575 consecutive patients with incident ALS
from a population-based registry in South-East England
register for ALS (SEALS) were studied. Their survival was
modelled as a two-step process: the time from diagnosis
to respiratory muscle involvement, followed by the time
from respiratory involvement to death. The effects of
predictor variables were assessed separately for each
time interval.
Findings Younger age at symptom onset, longer delay
from onset to diagnosis and riluzole use were associated
with slower progression to respiratory involvement, and
NIV use was associated with lower mortality after
respiratory involvement, each with a clinically signiﬁcant
effect size. Riluzole may have a greater effect in younger
patients and those with longer delay to diagnosis. A
patient’s survival time has a roughly 50% chance of
falling between half and twice the predicted median.
Interpretation A simple and clinically applicable
graphical method of predicting an individual patient’s
survival from diagnosis is presented. The model should
be validated in an independent cohort, and extended to
include other important prognostic factors.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS, also known as
motor neuron disease) is a degenerative disease of
the nervous system which is progressive, incurable
and almost always fatal. Around 1 in 400 people
will develop the condition, usually aged between 50
and 70 years.1 The cause is not well understood;
there is a signiﬁcant genetic component, but only a
minority of cases are due to single-gene mutations.2
The rate at which the condition progresses varies
greatly, as does the length of time from symptom
onset to death, from a few months to more than
10 years.3 It is therefore difﬁcult to advise a patient
on how long they may expect to live, and on the
uncertainty in this prediction, and not every patient
wants detailed information; nonetheless, for many
patients diagnosed with a life-limiting illness, such
an estimate is important for providing hope and
enabling them to plan their life and its ending, not
to mention improving the design and interpretation
of clinical trials. A recent systematic review3 and
more recent studies4–9 have found evidence that a
number of factors can help to predict longer sur-
vival in people with ALS. These include younger
age at symptom onset, longer delay from symptom
onset to diagnosis (diagnostic delay), limb onset as
opposed to bulbar onset, lack of cognitive impair-
ment, lack of respiratory muscle weakness, certain
genetic factors, and the baseline and slope of
certain laboratory measures and severity scores.
The evidence that gender and upper-limb onset (as
opposed to lower limb) can independently contrib-
ute to predicting survival is conﬂicting.
Three medical treatments have also been shown
to prolong survival: non-invasive ventilation (NIV)
when respiratory support is necessary, gastrostomy
feeding when dysphagia is present, and riluzole. As
a drug treatment which has been shown to prolong
survival in a neurodegenerative disease, riluzole is
of great theoretical as well as practical interest, but
it is not known whether the survival improvement
occurs throughout the disease course or only at
certain stages.
A practical way of combining the factors to
produce a good prediction for a particular individ-
ual would be of great use to the clinician and the
affected person. While there are many multivariate
survival analyses in the literature, most would
require the clinician to reconstruct the mathemat-
ical model (and in many cases the necessary infor-
mation is not given). Further, most use a Cox’s
proportional hazards model; in a similar study of
mortality in ALS,10 the use of such a model was
examined and found to be ‘clearly inadequate’, as
the effects of predictors including riluzole use were
found to vary with time from diagnosis, violating
the proportional hazards assumption. We know of
only two explicit predictive models, of which one11
requires data which would not usually be available
in the clinic, and the other12 omits important
predictors.
To develop such a model, one would need a
large population-based cohort of patients with
newly diagnosed ALS, with consistently recorded
data on the known prognostic factors and length of
survival, along with a robust statistical technique
requiring a minimum of arbitrary assumptions and
informed by understanding of the biology of the
disease. The South-East England register for ALS
(SEALS) registry provides such a data set, ascertain-
ing all cases of ALS in a population of some
3 million in the South-East of England. Full details
of the registry and case ascertainment are available
elsewhere.13
The dominant cause of death in ALS is respira-
tory muscle weakness, causing respiratory failure or
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infection: estimates range from 65% to 89%.14–19 The true pro-
portion is probably higher, as several studies investigating this
included categories such as ‘unexplained sudden death’ which
could well have a respiratory cause. As a simplifying assumption,
we therefore modelled the course of ALS in terms of four con-
secutive events: symptom onset, diagnosis, respiratory involve-
ment and death; our goal was to generate a clinically useful
model, able to inform clinicians and patients about survival.
METHODS
Cases and variables
The criteria for inclusion in the SEALS registry are described
elsewhere,13 but in brief, cases were included if they presented
between January 1990 and May 2013, and received a diagnosis
of ‘deﬁnite’ or ‘probable’ ALS according to the El Escorial cri-
teria.20 A few patients could not be included because they
experienced onset at two sites simultaneously, had respiratory
muscle weakness at onset or only received a diagnosis
postmortem.
We included in the model the most signiﬁcant and easily
assessed factors that have been found to be associated with sur-
vival, namely site of onset (bulbar, upper limb or lower limb),
age at symptom onset, gender, time from onset to diagnosis
(diagnostic delay) and treatment with riluzole. Riluzole use was
analysed as a binary variable: if a patient had ever taken riluzole,
it was coded as 1, otherwise 0. This method gives the closest
result parallel with the intention-to-treat method of analysis
used in clinical trials. Insufﬁcient information was available on
cognitive impairment, respiratory muscle weakness, genetic
status, use of NIV and gastrostomy feeding. Analyses relating to
survival in patients receiving NIV were performed using data
from patients attending the Motor Nerve Clinic at King’s
College Hospital, London (table 1), referred to below as the
‘NIV dataset’.
Summary of the statistical model
The technical details of the model are given below, but the rea-
soning behind it can be summarised as follows. We observed
that patients with ALS using NIV have a constant risk of death,
namely 20% per month in bulbar-onset cases and 10% per
month with limb onset; this does not change signiﬁcantly over
time. Noting that most deaths in ALS occur in the context of
respiratory muscle weakness, we inferred that this death rate
would apply from the onset of respiratory muscle involvement,
and that the rate would also be constant (albeit higher) in
patients with respiratory muscle weakness who were not using
NIV—we used data from the largest suitable study21 to estimate
how much higher.
Most patients do not have respiratory muscle involvement at
diagnosis, but develop it later on after a variable length of time.
We found that it ﬁtted the observed survival data very well if we
assumed that the logarithm of the time from diagnosis to
respiratory muscle involvement was normally distributed. Using
this model, we could ask whether the predictor variables (age at
symptom onset, diagnostic delay, riluzole use) were associated
with progression to respiratory muscle weakness, or separately
with mortality after respiratory muscle involvement.
Mortality after respiratory involvement
Our data did not include the date of onset of respiratory
involvement. We therefore examined Kaplan-Meier plots of the
NIV data set, which suggested that mortality in patients on NIV
(all of whom have respiratory involvement) is well modelled by
an exponential distribution, that is, a constant mortality rate, at
least until survival falls below 20% (ﬁgure 1). Extrapolating this
back, we treated mortality after respiratory involvement as con-
stant, and estimated the rate at 20% per month in bulbar-onset
cases and 10% per month in limb-onset cases, for patients using
NIV. We examined the prognostic factors for their association
with mortality in this data set using univariate exponential
regression.
For patients with respiratory involvement but not using NIV,
these mortality rates needed to be adjusted for the survival
beneﬁt of NIV. We were not able to estimate this survival beneﬁt
Table 1 NIV data set: descriptive statistics
Total cases n=128
Site of onset Bulbar 32 (25%) Limb 96 (75%)
Gender Female 37 (29%) Male 91 (71%)
Age at symptom onset (years) Median 57.0 IQR 50–64
Range 22–76
Diagnostic delay (months) Median 10.3 IQR 6.0–15.0
Range 1.0–55.1
Riluzole use Yes 32 (25%) No 96 (75%)
Survival from NIV initiation (months) Median 5.7 IQR 2.1–11.3
Range 0.1–38.9
NIV, non-invasive ventilation.
Figure 1 Constant-hazard ﬁtted post-non-invasive-ventilation (post-
NIV) survival curves in the clinic data set.
Figure 2 Reanalysis of data from Bourke et al.21 NIV, non-invasive
ventilation.
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using our data, and estimates in the literature vary widely. The
largest study is reported by Bourke et al,21 but the authors do
not explicitly derive a ﬁgure for survival beneﬁt. Fitting expo-
nential distributions to their Kaplan-Meier plots suggests a
3.5-fold survival beneﬁt for NIV (ﬁgure 2). On the basis of the
clinic audit data, we estimated that 80% of our patients accessed
NIV during their illness, and assumed this to be independent of
the covariates.
The combined model
Between the four modelled events (symptom onset, diagnosis,
respiratory involvement and death) lie three time intervals,
which were modelled separately. As our goal was to create a
clinically useful model, we chose to model survival from diagno-
sis, as it would be at least as useful as predicting from onset and
would allow us to use the time from symptom onset to diagno-
sis (diagnostic delay) as a predictor variable.
The effects of predictor variables on survival can be modelled
in two ways: as affecting the chance of death occurring at any
particular time (a Cox’s proportional hazards model) or as
affecting the length of time until death (an accelerated failure
time (AFT) model). In the case of time from diagnosis to
respiratory involvement, we were dealing with the progression
of a condition rather than the stochastic occurrence of an event,
and so an AFT model was appropriate.
To maximise the statistical power, we chose to use a paramet-
ric model with an a priori choice of modelling distribution. The
distribution of times from diagnosis to respiratory involvement
could not be visualised directly, but only in the context of the
combined model, so the choice of model distribution was arbi-
trary among those amenable to AFT analysis. AWeibull distribu-
tion was tried ﬁrst, resulting in a poor ﬁt; a log-normal
distribution gave a much better ﬁt. To avoid overﬁtting, the
log-normal distribution was chosen without trying other
distributions.
The overall survival time distribution was derived as the con-
volution of the log-normal distribution of time from diagnosis
to respiratory involvement with the cumulative exponential dis-
tribution of time from respiratory involvement to death.
Fitting the model
The combined model was then ﬁtted to the survival data. Two
parameters were allowed to vary in ﬁtting the model: the
log-scale mean of the log-normal distribution of time from diag-
nosis to respiratory involvement, and its SD. The mean was the
only parameter which was allowed to depend on the predictor
variables of age at symptom onset, diagnostic delay (log trans-
formed) and riluzole use. The model was ﬁtted by maximum-
likelihood estimation, using the ﬂexsurv package in R (C
Jackson. Flexsurv: Flexible parametric survival models.
R package version 0.2. 2013. http://cran.r-project.org/
package=ﬂexsurv).
Fitting the model to each group of patients according to
onset site (bulbar, upper limb or lower limb) gave substantially
closer ﬁts than the data set as a whole. This was due to a greater
spread (log-scale SD) of the log-normal distribution in the
limb-onset groups than in the bulbar-onset group. The two
limb-onset groups were practically identical in all analyses, so
we pooled the limb-onset groups but analysed the bulbar-onset
group separately.
All analyses were conducted and ﬁgures produced using R
2.15.2 (R Core Team. R: A language and environment for statis-
tical computing. Vienna, Austria: R Foundation for Statistical
Computing, 2012. ISBN 3-900051-07-0. http://www.r-project.
org/) running on Linux (Lubuntu 13.04).
RESULTS
Descriptive statistics and model ﬁt
A total of 575 patients were included. Very few cases were
excluded due to missing dates of birth, diagnosis or onset or
missing data on predictor variables; patients who remained alive
at the time of analysis were included, treating survival as cen-
sored, but in fact the date of death was known in 97% of cases
(table 2), so there was no risk of bias due to informative
censoring.
Table 2 shows summary statistics of the variables of interest in
the patient groups. These were comparable to cohorts from
other centres; for example, the median age at symptom onset
was 61.5 and the mean 60.7, which fall close to the average for
population-based cohorts.3 Table 3 shows the strengths of the
associations between them. In particular, there were mutual
associations between older age at symptom onset, bulbar onset
and female gender. Figure 3 shows Kaplan-Meier plots of sur-
vival time from diagnosis for the bulbar-onset and limb-onset
groups. In ﬁgure 4, the modelled survival curves are
Table 2 SEALS data set: descriptive statistics
Total cases n=575
Site of onset Bulbar 189 (33%) Limb 386 (67%)
Gender Female 239 (42%) Male 336 (58%)
Age at symptom onset (years) Median 61.5 IQR 54–69
Range 23–89
Diagnostic delay (months) Median 11.1 IQR 7.0–19.0
Range 1.0–296
Riluzole use Yes 260 (45%) No 315 (55%)
Survival from diagnosis (months) Median 17.7 IQR 8.3–29.9
Range 0.6–268
SEALS, South-East England register for amyotrophic lateral sclerosis.
Table 3 Pairwise associations between the variables
Bulbar onset Female gender Age at symptom onset Riluzole Log diagnostic delay
Bulbar onset 1.93 5.83 0.69 −0.26
Female gender 1.4 to 2.8 2.49 0.73 0.05
Age at symptom onset 3.9 to 7.8 0.5 to 4.5 −6.08 −0.06
Riluzole 0.5 to 1.0 0.5 to 1.0 −8.0 to −4.2 −0.07
Log diagnostic delay −0.4 to −0.1 −0.1 to 0.2 −0.1 to 0.02 −0.2 to 0.1
The figures in the upper triangle represent the strength of association between each pair of variables. Where both variables are binary (onset site, gender, riluzole), the OR is given;
where one is continuous (age, delay) and one binary, the difference in means is given; where both are continuous, Pearson’s r is given. In each case, the 95% CI is given in the
corresponding cell in the lower triangle. Figures in bold represent associations for which the CI does not include the null effect (unity for ORs, zero otherwise).
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superimposed on these plots, suggesting an excellent ﬁt of the
model to the data.
Mortality in patients on NIV
No signiﬁcant associations were found between mortality in the
NIV data set and age at symptom onset, diagnostic delay, gender
or riluzole use (table 4), and we therefore did not include these
variables in the mortality part of the combined model.
However, because of the relatively small sample size, the CIs are
large, and the analysis does not rule out the possibility of clinic-
ally important effects.
Progression to respiratory involvement
Age, diagnostic delay and riluzole use were each independently
associated with slower progression from diagnosis to respiratory
involvement. This held true in univariate (table 5) and multi-
variate (table 6) analyses, for bulbar-onset and limb-onset
cases separately, and the effect sizes were all clinically relevant
(ﬁgure 5). No signiﬁcant effect was found for gender.
Riluzole appears to have a greater beneﬁt, even in ratio terms,
in younger patients and in those with longer diagnostic delay
(ie, in patients with longer predicted survival; ﬁgure 5). In an
unplanned post hoc analysis, statistically signiﬁcant interaction
effects were found in the limb-onset group but not the bulbar-
onset group, although the effect size estimates were slightly
larger in the bulbar-onset group.
Using the graphs to predict survival in clinic
To predict the survival time of a patient at diagnosis, we suggest
the following procedure. If the patient already has respiratory
involvement, their mortality is given simply by 20% per month
if there is bulbar involvement, or 10% per month if there is
not; if the patient is not using NIV, these ﬁgures increase to
54% and 31%, respectively. For patients without respiratory
involvement, ﬁgure 5 gives the predicted median survival time,
which can be used to estimate 50% CI for the estimate: the sur-
vival time for half of cases will fall between half the median and
twice the median.
For example, if ﬁgure 5 suggests a median survival of
12 months from diagnosis for a particular patient, there is a
50% chance that they will survive for between 6 and
24 months. At the time of diagnosis, riluzole use will not
usually be known: the model allows prediction with and
without riluzole, giving the clinician and patient a useful esti-
mate of the effect of riluzole in the individual case.
Eighty per cent of our cases had an age at symptom onset
between 45 and 75, and 80% had a diagnostic delay between 5
and 30 months. The model should be interpreted with caution
for cases lying outside these ranges.
Testing for robustness
Although AFT models are considered relatively robust in
general, we wished to test our model in detail.
To examine the sensitivity of the model to changes in the
data, the analyses were rerun many times, removing 20% of
cases at random each time. For post-NIV mortality, 95% of the
500 resulting estimates lay between 17.1% and 24.4%
Figure 3 Raw Kaplan-Meier survival curves for the bulbar-onset and
limb-onset groups.
Figure 4 Fitted survival curves.
Table 4 Effects of covariates on survival in patients on NIV:
univariate analyses
Variable Comparison
Survival
benefit
estimate
Survival
benefit 95%
CI
p
Value
Age at
symptom
onset
Across IQR
(69 cf. 54)
1.02 0.79 to 1.31 0.89
Log
diagnostic
delay
Across IQR (19 m
versus 7 m)
1.14 0.91 to 1.43 0.24
Gender Male cf. female 1.40 0.94 to 2.07 0.09
Riluzole Yes cf. no 1.38 0.92 to 2.08 0.12
NIV, non-invasive ventilation.
Table 5 Effects of covariates on time from diagnosis to respiratory
involvement: univariate analyses
Variable
Onset-site
group Coefficient 95% CI p Value
Age at symptom
onset (years)
Bulbar −0.0235 −0.030 to −0.017 1×10−12
Limb −0.0253 −0.031 to −0.020 1×10−18
Diagnostic delay
(months)
Bulbar 0.226 0.11 to 0.35 3×10−4
Limb 0.166 0.07 to 0.26 9×10−4
Riluzole use Bulbar 0.328 0.15 to 0.51 3×10−4
Limb 0.408 0.22 to 0.60 2×10−5
Male gender Bulbar −0.068 −0.25 to 0.12 0.5
Limb 0.007 −0.18 to 0.19 0.9
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(bulbar onset) or 8.6% and 10.8% (limb onset) monthly mortal-
ity. The results for the combined model are shown in table 6; in
general, more than 95% of the estimates lie within the 95% CI
of the primary analysis. It is also strongly reassuring that the
estimated effect size of each predictor variable was practically
the same in the bulbar-onset and limb-onset groups.
The ﬁgures for the survival beneﬁt of NIV (3.5×), and for
the proportion of our cases who received NIV (80%), were
derived from sources external to the study. Varying these ﬁgures
within ranges of 2× to 6× and 50–90%, respectively, the coefﬁ-
cients for age at symptom onset, diagnostic delay and riluzole
all remained within 22% of the values from the main analysis.
The choice of a log-normal distribution to model time from
diagnosis to respiratory involvement was arbitrary. However, the
ﬁt remained good when the data were stratiﬁed by the predictor
variables, and the distribution also ﬁtted well to the data
derived from the patients attending the Motor Nerve Clinic at
King’s College Hospital, London (of which the NIV data set
used in the present study was a subset; ﬁgure 6). This cohort is
not suitable for validating the model as a whole, since it is not
population based and partially overlaps with the SEALS cohort,
but it helps to conﬁrm that the shape of the chosen distribution
was appropriate.
DISCUSSION
Findings
We present a straightforward graphical method of predicting a
patient’s survival time from ALS diagnosis, taking into account
the known prognostic factors of onset site, age at symptom
onset, diagnostic delay, riluzole use, NIV use and respiratory
muscle involvement. The model may predict a median survival
of as much as 4 years or as little as 8 months, and even less in
patients with respiratory involvement. The true survival time
falls between half and twice the median in about half of the
patients. Pending validation of the model, we propose this as a
clinically useful tool.
Comparison with existing models
The present study improves on the existing prognostic models
in several important ways. We give an explicit, straightforward
method which can be applied in the clinic in moments, without
specialised tests or detailed calculation. It provides an
Table 6 Effects of covariates on time from diagnosis to respiratory involvement: multivariate analysis
Variable Onset-site group Coefficient 95% CI (main analysis) 95% CI (80% sample) p Value (main analysis)
Baseline mean Bulbar 4.43 2.7 to 7.3 3.5 to 5.9
Log scale Limb 4.86 3.3 to 7.1 3.9 to 6.2
Baseline SD Bulbar 0.97 0.85 to 1.11 0.89 to 1.03
Log scale Limb 1.32 1.19 to 1.48 1.24 to 1.37
Age at symptom onset (years) Bulbar −0.0185 −0.025 to −0.012 −0.022 to −0.016 2×10−9
Limb −0.0223 −0.028 to −0.017 −0.026 to −0.019 9×10−16
Diagnostic delay (months) Bulbar 0.130 0.039 to 0.220 0.079 to 0.174 0.005
Limb 0.140 0.063 to 0.215 0.094 to 0.180 0.0003
Riluzole use Bulbar 0.228 0.077 to 0.380 0.16 to 0.29 0.003
Limb 0.205 0.057 to 0.353 0.12 to 0.29 0.006
Figure 5 Effects of predictors on
time to respiratory involvement.
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individualised estimate, not merely a broad prognostic category,
along with a guide to the uncertainty in this estimate which is
easy to calculate and interpret. Using a large population-based
cohort avoids biases associated with referral to and treatment in
a specialist clinic; we avoid making the proportional hazards
assumption, found to be invalid in a similar study;10 and our
main analysis is multivariate, taking into account all predictor
variables at the same time. Finally, and crucially, it can readily
be validated by other investigators in independent cohorts of
patients.
Riluzole use was associated with slower progression to
respiratory involvement in this study. Riluzole is known to
prolong overall survival in ALS, but its effects on particular
stages of the condition have not previously been reported.
While our data do not rule out a continuing effect of riluzole
on mortality after respiratory involvement, this ﬁnding empha-
sises the importance of starting riluzole treatment as soon as
possible after diagnosis. Our analysis also suggests that riluzole
may be especially beneﬁcial for younger patients and those with
longer diagnostic delay.
The association of bulbar onset with shorter median survival
is accounted for by higher mortality after respiratory involve-
ment, a higher average age at symptom onset and less use of
riluzole in the bulbar-onset group. Patients with bulbar weakness
are at higher risk of aspiration and respiratory tract infection, a
common mode of death; they are also less likely to tolerate NIV.
While the present analysis related to bulbar involvement at
onset, it is clinically plausible that the effect on mortality would
be seen in any patients who have bulbar weakness at the time of
respiratory involvement. We have not found evidence that
patients with bulbar-onset progress to respiratory involvement
sooner, after allowing for age and riluzole use.
The effects of known prognostic factors were conﬁrmed in our
model, with similar effect sizes: for example, a recent study22
found a 26% reduction in hazard for riluzole, which is consistent
with ﬁgure 5. Since our statistical methods have not been used
previously in this context, this provides a check on our methods
and indirectly supports the novel ﬁndings of this study.
Limitations
Like any model, the present study represents a compromise
between simplicity and robustness on the one hand, and the
faithful representation of reality on the other.
There is evidence that patients with upper motor neuron fea-
tures alone12 or lower motor neuron features alone12 22–24 tend
to survive longer, and that those with cognitive impairment,25
neck weakness,26 weight loss at diagnosis6 and certain geno-
types27 28 have a higher overall mortality. Our study did not
include information on these factors.
In constructing the model, we assumed that the patients did
not have respiratory muscle involvement at diagnosis. This biases
our model slightly towards predicting shorter survival in those
without respiratory involvement. The basic assumption that
respiratory involvement always occurs before death will also have
exceptions. The availability and use of gastrostomy and NIV may
vary between centres, as well as other aspects of care relevant to
survival.29 The model does not take account of such variation.
Although we tried to avoid bias by using a population-based
cohort, one must always be cautious in applying a model to
populations other than the one from which it was derived.
The model is useful for predicting survival at the time of
diagnosis, and once respiratory involvement has occurred; the
prediction of survival at other times during a patient’s illness is
not addressed by the model.
The present study is not a clinical trial, and therefore the
effect of riluzole use should be interpreted cautiously as ‘those
who receive riluzole survive longer’ rather than as ‘riluzole pro-
longs survival’, though both are consistent with the data.
A weakness of this study is that the population studied has a
lower median age of onset than is typical for population regis-
ters. This may reﬂect underascertainment of older age groups,
which would be consistent with the lifetime risk curves previ-
ously reported.1 30 It may alternatively reﬂect the inﬂuence of
London, which is a large component of the catchment and
being urban, has a younger population than average. A further
weakness is that the risk curves have been derived in a popula-
tion study but will be most likely applied in a clinic setting, and
clinics have a generally younger, more male population, which
may limit its applicability.
Future work
Our model makes quantitative statements about the effects of
prognostic factors on the distribution of survival time in ALS,
and suggests the speciﬁc testable hypotheses that riluzole treat-
ment may be more beneﬁcial in patients who do not yet have
respiratory involvement, in younger patients and in those with
longer diagnostic delay. Analysis of an independent population-
based cohort is necessary to investigate these ﬁndings and
predictions.
Instead of using mortality data, the speed of progression of
ALS can also be assessed using the time from clinical onset to
the time of involvement of the second site. We would predict
that age, diagnostic delay and riluzole use would be associated
with this, but that gender and site of onset would not have clin-
ically signiﬁcant independent effects.
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